Display options
Cite
Ionta MT, Perra MT, Atzori F, et al. Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients. Exp Ther Med. 2010;1(1):59-64doi: 10.3892/etm_00000010.
Ionta, M. T., Perra, M. T., Atzori, F., Maxia, C., Pusceddu, V., Demurtas, P., Deidda, M. C., Piras, F., Frau, B., Murtas, D., Minerba, L., Massidda, B., & Sirigu, P. (2010). Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients. Experimental and therapeutic medicine, 1(1), 59-64. https://doi.org/10.3892/etm_00000010
Ionta, Maria Teresa, et al. "Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients." Experimental and therapeutic medicine vol. 1,1 (2010): 59-64. doi: https://doi.org/10.3892/etm_00000010
Ionta MT, Perra MT, Atzori F, Maxia C, Pusceddu V, Demurtas P, Deidda MC, Piras F, Frau B, Murtas D, Minerba L, Massidda B, Sirigu P. Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients. Exp Ther Med. 2010 Jan;1(1):59-64. doi: 10.3892/etm_00000010. Epub 2010 Jan 01. PMID: 23136593; PMCID: PMC3490395.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2010 Jan;1(1):59-64. doi: 10.3892/etm_00000010. Epub 2010 Jan 01.

Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients.

Experimental and therapeutic medicine

Maria Teresa Ionta, Maria Teresa Perra, Francesco Atzori, Cristina Maxia, Valeria Pusceddu, Paolo Demurtas, Maria Cristina Deidda, Franca Piras, Barbara Frau, Daniela Murtas, Luigi Minerba, Bruno Massidda, Paola Sirigu

Affiliations

  1. Departments of Medical Oncology.

PMID: 23136593 PMCID: PMC3490395 DOI: 10.3892/etm_00000010

Abstract

A large proportion of human tumors show deregulated expression of a variety of proteins that play a crucial role in the execution of the apoptotic program. Survivin belongs to the family of inhibitor of apoptosis proteins which were originally identified in baculoviruses. Ectopic expression of survivin conveys resistance to apoptosis to a variety of stimuli, and survivin is one of the most abundantly overexpressed genes in human tumors such as breast cancer. In this study we examined the expression of survivin protein in a series of T4 breast cancers to identify any correlation with long-term patient outcomes. Moreover, we investigated the hypothesis of a possible association between p53 and survivin as a factor further complicating the outcome. Archival specimens from 53 T4 breast cancer patients were included in the study and treated for the immunohistochemical localization of survivin and p53 using the streptavidin-biotin alkaline phosphatase method. The immunoreactivity was evaluated semiquantitatively according to the percentage of cells stained. Forty percent of tumors were positive for survivin. Statistical analysis revealed that survivin expression negatively influenced the 5- and 10-year disease-free and overall patient survival. In multivariate analysis, survivin expression was a significant independent prognostic indicator of worse outcome in overall survival [hazard ratio (HR)=2.61]. Our results showed that survivin is associated with a worse prognosis in patients with T4 breast cancer, and remarkably its prognostic relevance is maintained even long-term. Notably, p53 (HR=3.2) seems to negatively enhance the effect of survivin on survival.

References

  1. Clin Cancer Res. 2000 Jan;6(1):127-34 - PubMed
  2. J Biol Chem. 1994 Feb 4;269(5):3139-42 - PubMed
  3. Clin Cancer Res. 2008 Dec 15;14(24):8019-26 - PubMed
  4. Cancer Lett. 2006 Dec 8;244(2):164-71 - PubMed
  5. Pathobiology. 2008;75(2):132-9 - PubMed
  6. J Cancer Res Clin Oncol. 2005 Aug;131(8):504-10 - PubMed
  7. Neuropathol Appl Neurobiol. 2007 Feb;33(1):67-76 - PubMed
  8. Lab Invest. 1999 Nov;79(11):1327-33 - PubMed
  9. J Cell Physiol. 2006 Sep;208(3):476-86 - PubMed
  10. Clin Cancer Res. 2008 May 1;14(9):2681-9 - PubMed
  11. Am J Pathol. 1998 Jan;152(1):43-9 - PubMed
  12. Cancer Lett. 2003 Nov 25;201(2):225-36 - PubMed
  13. J Am Coll Surg. 1995 Mar;180(3):297-306 - PubMed
  14. Clin Cancer Res. 2008 Aug 15;14(16):5000-5 - PubMed
  15. Br J Cancer. 2006 Jan 16;94(1):108-14 - PubMed
  16. Br J Cancer. 2007 Feb 26;96(4):639-45 - PubMed
  17. J Clin Invest. 2004 Oct;114(8):1117-27 - PubMed
  18. Cancer Res. 2000 Jun 1;60(11):2805-9 - PubMed
  19. Br J Cancer. 2003 Apr 7;88(7):1077-83 - PubMed
  20. Br J Cancer. 1977 Mar;35(3):292-8 - PubMed
  21. Nat Med. 1997 Aug;3(8):917-21 - PubMed
  22. Biochemistry. 1994 Nov 22;33(46):13848-55 - PubMed
  23. Oncogene. 2002 Apr 18;21(17):2613-22 - PubMed
  24. Histopathology. 2007 Jun;50(7):835-42 - PubMed

Publication Types